Point mutations of the N-ras oncogene are relatively common in acute myelogenous leukemia (AML) cells, occurring in some 25% to 50% of patient samples. We used a technique involving the direct nucleotide sequencing of in vitro amplified N-ras genomic fragments to determine the frequency of N-ras point mutations in chronic myeloid leukemia (CML) cells at various stages of the disease. This approach will detect N-ras point mutations in a mixed population of cells if the mutation is present in 25% or more of the cells. We could not demonstrate any point mutation at N-ras codons 12,13 or 59–63 in any of the 44 CML cases analyzed, which included 21 blast crisis samples. In contrast with AML N-ras point mutations are exceedingly rare in CML.
Rare occurrence of N-ras point mutations in Philadelphia chromosome positive chronic myeloid leukemia
- Share Icon Share
- Tools Icon Tools
- Search Site
- PDF LinkPDF
SJ Collins, M Howard, DF Andrews, E Agura, J Radich; Rare occurrence of N-ras point mutations in Philadelphia chromosome positive chronic myeloid leukemia. Blood 1989; 73 (4): 1028–1032. doi: https://doi.org/10.1182/blood.V73.4.1028.bloodjournal7341028
Download citation file: